HOME >> MEDICINE >> NEWS
Comparison of 4 diet plans shows better outcomes for diet with lowest carbohydrate intake

Premenopausal women who were assigned to follow the Atkins diet for one year lost more weight when compared to women who were assigned to follow the Zone, Ornish and LEARN diets, according to a study in the March 7 issue of JAMA.

Overweight and obesity are well-documented problems in the United States. National dietary weight loss guidelines (a diet low in calories and fat, high in carbohydrates) have been challenged, particularly by supporters of low-carbohydrate diets. However, limited evidence has been available to effectively evaluate other diets, according to background information in the article.

Christopher D. Gardner, Ph.D., of Stanford University Medical School, Stanford, Calif., and colleagues examined the effects of four diets-3 popular and substantially different diets and 1 diet based on national guidelines-representing a spectrum of carbohydrate intake, on weight loss and related metabolic variables in overweight and obese premenopausal women. The diets were Atkins (very low in carbohydrate), Zone (low in carbohydrate), LEARN (Lifestyle, Exercise, Attitudes, Relationships, and Nutrition; low in fat, high in carbohydrate, based on national guidelines), and Ornish (high in carbohydrate). The study, which included 311 overweight/obese (body mass index, 27-40) nondiabetic, premenopausal women, was conducted from February 2003 to October 2005. Participants were randomly assigned to follow for 12 months the Atkins (n = 77), Zone (n = 79), LEARN (n = 79), or Ornish (n = 76) diets and received weekly instruction for 2 months, then an additional 10-month follow-up.

Besides weight loss, the participants were also measured for lipid profile (low-density lipoprotein, high-density lipoprotein, and non-high-density lipoprotein cholesterol, and triglyceride levels), percentage of body fat, waist-hip ratio, fasting insulin and glucose levels, and blood pressure. Outcomes were assessed at months 0, 2, 6, and 12.

The researc
'"/>

Contact: Susan Ipaktchian
650-725-5375
JAMA and Archives Journals
6-Mar-2007


Page: 1 2

Related medicine news :

1. Comparison of obstetric outcomes between on-call and patients own obstetricians
2. Comparison of patients access to new and better cancer drugs reveals inequalities between countries
3. Comparison of drug-releasing coronary stents show similar effectiveness
4. Research probes seniors plans for end-of-life care
5. Consumer-driven health plans slow to catch on, 2nd annual survey finds
6. Extra payments to Medicare Advantage plans totaled $5.2 billion over fee-for-service costs in 2005
7. Specific strategic plans ensure timely emergency care for heart attack patients
8. Racial disparities high in Medicare plans
9. Medicare Advantage plans not always a good deal
10. Study highlights gaps in Europes preparedness plans for pandemic influenza
11. UK plans for pandemic flu dont go far enough

Post Your Comments:
(Date:7/30/2014)... New York City, NY (PRWEB) July 30, 2014 ... Memorial & Museum at Ground Zero, the Ground Zero Museum ... confusion in recent tour bookings. Says the Museum Workshop's Carole ... tour and museum on all the major travel sites who ... Our description is now crystal clear as to what we ...
(Date:7/30/2014)... NY, July 30, 2014We have pills to ease pain, to ... conditions, and to enhance our sexual and athletic prowess. Why ... and could we benefit from taking fewer pills? This provocative ... The Role and Fantasy of Pills in Modern Medicine ," ... , a peer-reviewed publication from Mary Ann Liebert, Inc., publishers. ...
(Date:7/30/2014)... WEDNESDAY, July 30, 2014 (HealthDay News) -- Medical costs ... States are more than $32 billion each year, according ... Control and Prevention. The yearly financial toll of ... to reach an estimated $49 billion by 2020. ... for COPD, which provide state public health practitioners with ...
(Date:7/30/2014)... in Manchester have identified a protein that could help ... a treatment that makes radiotherapy more effective, according to ... Cancer (BJC). , The team from The University ... that patients whose bladder tumour had high levels of ... from having carbogen oxygen mixed with carbon dioxide ...
(Date:7/30/2014)... Up to 20 percent of Parkinson,s disease (PD) ... but largely unrecognized challenge: the occurrence of impulse ... behavior, eating, or spending. Yet the presence of ... complicate treatment options. A team of investigators from ... of Pennsylvania and the Parkinson,s Disease Research, Education ...
Breaking Medicine News(10 mins):Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 2Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 3Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 4Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 5Health News:Annual COPD Costs To Hit $49 Billion by 2020: CDC 2Health News:Scientists pinpoint bladder cancer patients who could benefit from 'tumor-softening' treatment 2Health News:Penn researchers: Naltrexone may diminish impulse control disorders in Parkinson's disease patients 2
(Date:7/30/2014)... 30, 2014 Stryker brand ambassadors Fred Funk ... 3M Championship Champions Tour event near Minneapolis, MN ... Blaine . Stryker is the official joint replacement products company ... Friday, August 1 st through Sunday, August 3 rd , ... on-site joint health destination located in the Pioneer Press Expo tent ...
(Date:7/30/2014)... PARIS , July 30, 2014 /PRNewswire/ ... Sanofi (EURONEXT: SAN and NYSE: SNY ) ... of alirocumab in people with hypercholesterolemia met their primary ... in low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared ... monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
(Date:7/30/2014)... and SAN DIEGO , July 30, 2014 ... ARNA ) announced today that an article based on post-hoc ... entitled, "Early Weight Loss While on Lorcaserin, Diet, and Exercise ... published in the online issue of Obesity , the ... of these analyses was to identify whether there is an ...
Breaking Medicine Technology:Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 2Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 3Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 4Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7
Cached News: